Table 1 Clinical scores in the EAE model after GA and sPIF treatments.

From: Synthetic PreImplantation Factor (sPIF) induces posttranslational protein modification and reverses paralysis in EAE mice

 

Mean Clinical Score

Peak Paralysis

Mean Clinical Score End

Time Point 1 26 days

EAE

1.36 ± 0.22

2.5 ± 0.33

1.3 ± 0.44

EAE + GA

1.3 ± 0.15

2.4 ± 0.33

1.6 ± 0.44

EAE + sPIF

0.95 ± 0.19

2.1 ± 0.23

*0.60 ± 0.22

Time Point 2 41 days

EAE

1.01 ± 0.19

1.0 ± 0.28

1 ± 0

EAE + GA

0.80 ± 0.11

1.85 ± 0.23

1.4 ± 0.6

EAE + sPIF

*0.45 ± 0.08

0.91 ± 0.14

*0.5 ± 0.18

Time Point 3 50 days

EAE

2.6 ± 0.20

4.37 ± 0.18

2.12 ± 0.85

EAE + GA

2.4 ± 0.15

4.33 ± 0.16

2.44 ± 0.53

EAE + sPIF

*1.2 ± 0.10

*3 ± 0.33

*0.66 ± 0.55

  1. Clinical score analysis of sPIF and GA at the three different time points in EAE mice. We ended the experiment at Time Point 1: 26 days, Time Point 2: 41 days, and Time Point 3: 50 days. For further analyses we selected Time Point 3 as the effect of sPIF was profound. MCS = mean clinical score, PP = peak paralysis, MCE = mean clinical score end. sPIF: synthetic PreImplantation Factor; GA: glatiramer acetate. EAE: experimental autoimmune encephalomyelitis. Data is expressed as mean +/− SEM. sPIF, GA and PBS: n = 7–18 per group. *p < 0.05 compared to EAE. Control (healthy animals) are not presented as the score was 0.
Back to article page